Xilis

About Xilis

Xilis develops next-generation ex vivo technology to accelerate and de-risk drug development from discovery to clinical trials, with a focus on patient-derived 3D microorganoSphere platforms for functional precision oncology. Their MOS technology preserves the cellular composition and biological richness of primary tissues to enable more accurate and rapid predictions of efficacy across multiple therapeutic modalities. The company operates in the United States, headquartered in Durham, North Carolina, and serves pharmaceutical, biotech, and academic partners through technology licensing and collaboration in drug discovery and development.